|
Objective: study of recombinant human vascular endothelial to Inhibin of Hela cells in vitro proliferation and invasion, to explore its mechanisms and of VEGF, MMP-9 relationship, and thus provide some theoretical and experimental clinical cervical cancer targeted therapy basis. Method: 1, different concentrations of recombinant human vascular endothelial to inhibit hormone (1,5,10,100 μg / ml) for 24, 48 and 72 hours after the inhibition of Hela cells in vitro, and inhibition rate was determined by MTT assay. 2, cells scratches were observed 1μg/ml, 10μg/ml, 100μg/ml, recombinant human vascular endothelial cells scratches inhibit hormone group 24 hours after the migration. 3,1 μg / ml, 10μg/ml, 100μg/ml recombinant human vascular endothelial inhibin deal with Hela cells 24 hours after RNA extraction and reverse transcription polymerase chain reaction (RT-PCR), semi-quantitative determination of Hela cells VEGF and MMP-9 mRNA expression. The results: 1, MTT prime role 1,5,10,100 μg / ml of recombinant human endostatin 24,48 and cell growth after 72 hours are subject to varying degrees of inhibition in a dose-and time-dependent manner, in each experimental group and control group significantly different (p lt; 0.05) after 24 h of scratches control group cells basically overwrite the original scratches, scratches width significantly narrowed. The experimental group (1,10,100 μg / ml) with recombinant human vascular endothelial inhibit hormone concentration increases, gradually narrowing the distance Hela cells migrate to the scratch area, significant differences in the presence of a control group. 3, RT-PCR is shown in each experimental group (1μg/ml, 10μg/ml, 100μg/ml) expression of VEGF mRNA expression with increasing concentrations gradually decreased gray value (0.151 ± 0.165,0.066 ± 0.150,0.002 ± 0.012) significantly lower than the control group (0.340 ± 0.184). Tandem with increasing concentrations of MMP-9 mRNA expression decreased gray value (0.759 ± 0.006,0.561 ± 0.007,0.198 ± 0.025) were significantly lower than the control group (1335 ± 0.043). Each experimental group and negative control group and the experimental group compared to the expression differences were statistically significant (P lt; 0.01). Conclusion: The recombinant human vascular endothelial inhibin inhibit the proliferation of Hela cells in vitro, in a time-and dose-dependent manner. Recombinant human vascular endothelial inhibition could inhibit the migration of Hela cells and Hela cells of VEGF can inhibit the expression of MMP-9 mRNA. Inferred recombinant human vascular endothelial inhibiting hormone might act by inhibiting tumor metastasis-related factors, VEGF, MMP-9 expression, to suppress the invasion and metastasis of cervical cancer.
|